



November 11, 2014

Esperion Therapeutics to Host and Webcast Live Investor Event

- Event to be held in Chicago, location of 2014 American Heart Association Scientific Sessions
- Webcast on Monday, November 17, 2014 at 7:30 p.m. Central Time/8:30 p.m. Eastern Time

ANN ARBOR, Mich.--(BUSINESS WIRE)-- Esperion Therapeutics, Inc. (NASDAQ: ESPR), an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic risk markers, today announced it will host an investor event and live webcast to discuss the ETC-1002 development program, including the Phase 2b ETC-1002-008 results announced last month. Perspectives will be provided by featured speaker Mark E. McGovern, M.D., FACC, former executive vice president, medical affairs, and chief medical officer of KOS Pharmaceuticals; Tim M. Mayleben, president and chief executive officer of Esperion; and members of the Esperion management team. The event will take place on Monday, November 17, 2014 at 7:30 p.m. Central Time/8:30 p.m. Eastern Time in Chicago, IL, coinciding with the American Heart Association Scientific Sessions.

The event can be accessed by dialing (877) 831-3840 (domestic) or (253) 237-1184 (international) five minutes prior to the start of the event and providing access code 34444121. A live, listen-only webcast of the presentation can be accessed on the investor relations section of the Esperion website at www.esperion.com. A webcast replay of the presentation will be available approximately one hour after completion and will be archived on the Company's website.

Esperion's Commitment to Cardiometabolic Disease

Esperion is committed to improving the lives of patients with cardiometabolic diseases. The Esperion team leverages its understanding of, and experience with, key biological pathways to discover and develop innovative therapies for the treatment of patients with hypercholesterolemia who have uncontrolled cholesterol levels despite the use of currently available therapies. Esperion has assembled a portfolio of programs including one product candidate in late-stage clinical evaluation (ETC-1002) and two pre-clinical product candidates.

About Esperion Therapeutics

Esperion Therapeutics, Inc. is an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral, LDL-cholesterol lowering therapies for the treatment of patients with hypercholesterolemia and other cardiometabolic risk markers. ETC-1002, Esperion's lead product candidate, is a unique, first-in-class, orally available, once-daily small molecule designed to lower LDL-cholesterol levels and avoid the side effects associated with therapies currently available for lowering LDL-cholesterol. ETC-1002 is being developed for patients with hypercholesterolemia, including those with a history of statin intolerance. For more information, please visit www.esperion.com and follow us on Twitter at <https://twitter.com/EsperionInc>.

Media Contact:
W2O Group
Elliot Fox
212.257.6724
efox@w2ogroup.com

or
Investor Contact:
Esperion Therapeutics, Inc.
Mindy Lowe
734.887.3903
mloew@esperion.com

Source: Esperion Therapeutics, Inc.

News Provided by Acquire Media